D-SOLVE: Study of Hepatitis D treatments
Part of Digestive system, Infections clinical trials.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for antibodies that show you have been infected with the hepatitis D virus.
- You must be at least 18 years old.
- People of any sex or gender can join.
- You must be willing to agree to all study-related procedures after learning about them.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood markers in people with hepatitis D who are already taking BLV (bulevirtide) to better understand the infection. It may help doctors learn more about how the virus changes over time.
This study uses a mobile diary app to track symptoms and quality of life for people living with hepatitis D infection. It may help researchers better understand the patient experience.
This study follows adults with long-term (chronic) hepatitis B to better understand the condition over time. If you have chronic hepatitis B, it may help researchers improve care for people with the infection.
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
This study follows adults who have ongoing hepatitis D infection along with hepatitis B. It aims to better understand this mixed infection and how these patients do over time.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
Hear when a new HDV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.